lemme glp 1 alternative GLP-1 Drugs from the Gray Market Abbey Sharp • Registered Dietitian

OZEMs fourth-largest holding, with a 4.41% weighting, Viking Therapeutics NASDAQ: VKTX, currently has its dual GLP-1/GIP agonist, VK2735, in advanced clinical trials for obesity and metabolic disorders

And as further data from Gallup shows, more and more Americans are trying these drugs, with the survey finding that more than 12 percent of adults reported taking them in the second and third quarters of 2025, up from less than 6 percent in early 2024

[DOI] [PubMed] [Google Scholar] 67.Feetham CH, Ai M, Culotta I, et al

( 10.1210/endrev/bnaa032) [DOI] [PMC free article] [PubMed] [Google Scholar] McLean BA Wong CK Kaur KD Seeley RJ & Drucker DJ

While Eli Lilly saw the results as indicators of success, investors on the call expressed concerns